Repositioning Candidate Details
| Candidate ID: | R0864 |
| Source ID: | DB05758 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | CYT007-TNFQb |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis. The vaccine should allow for administration of low amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in psoriasis and psoriatic disorders. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | CYT007-TNFQb is designed to instruct the patient’s immune system to produce an anti-TNF-α antibody response. The induced antibodies aim to bind and neutrolize soluble TNF-α in order to inhibit its inflammatory activity. That way, the subsequent inflammatory process should be slowed down and the deterioration of skin or other tissues reduced. |
| Targets: | Tumor necrosis factor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|